Overview

An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy

Status:
Approved for marketing
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, single-arm, expanded access program (EAP) designed to provide atezolizumab access to participants with locally advanced or metastatic urothelial carcinoma that has progressed on, or is intolerant to, a platinum-containing chemotherapy regimen.
Details
Lead Sponsor:
Genentech, Inc.
Treatments:
Antibodies, Monoclonal
Atezolizumab